GSK lightens portfolio, shrinks footprint

Share this article:
GSK lightens porfolio, shrinks footprint
GSK lightens porfolio, shrinks footprint

GlaxoSmithKline is selling thrombosis meds Arixtra and Fraxiparine to the Aspen Group, a longtime partner in GSK's ongoing effort to transfer drugs from its books to another entity. The company said in a statement Monday that the deal will include $1.3 million in cash and that it transfers global rights, with few exceptions, to the products and to a manufacturing site (the Notre Dame de Bondeville site) and “certain dedicated commercial employees.” GSK said in a statement that the deal “is a further example of GSK's commitment to increase focus on products with the most growth potential.”

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.